A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
Purpose
A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)
Condition
- Metabolic Dysfunction-associated Steatohepatitis (MASH)
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participant is capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol - Must be 18 to 75 years of age (inclusive) at Screening - Body Mass Index (BMI) of 25 to <40 kg/m2 (inclusive) - Male participants must agree to use a highly effective contraception during the Treatment Period and at least 12 months after administration of VV-14303. Female participants must not be a woman of child-bearing potential (WOCBP) - Biopsy-confirmed MASH - Previous history or presence of ≥2 of the following metabolic risk factors: obesity (BMI ≥25 kg/m²), hypertension (blood pressure [BP] ≥140/90 mmHg or on antihypertensive medication), dyslipidemia (triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol [HDL-C] <40 mg/dL in men/<50 mg/dL in women or on lipid-lowering therapy), type 2 diabetes mellitus - Must be willing to refrain from the donation of blood, plasma, platelets, eggs, or sperm during the 12-month post-treatment follow-up period
Exclusion Criteria
- Presence of alternate and/or additional liver disease etiologies at Screening, including but not limited to chronic viral hepatitis, autoimmune hepatitis - Use of treatments for metabolic syndrome management, including oral antidiabetic drugs (OADs) (e.g., metformin), incretin mimetics (GLP-1 receptor agonists or GLP-1/gastric inhibitory polypeptide [GIP] agonists) or other glucose-lowering agents that has not been stable for at least 6 months prior to Screening - Use of Resmetirom that has not been stable for at least 6 months prior to Screening visit - Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate. - Type 1 diabetes, or poorly controlled type 2 diabetes (HbA1c > 8.0% at Screening) - History of major trauma to the muscle(s) intended for IM injection meeting any of the following criteria: 1. Within 6 months prior to Screening, or 2. At any timepoint prior to Screening with continued neurologic or musculoskeletal symptoms - Prior participation in any systemic experimental treatment or receiving any other systemic investigational treatment including within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of Screening - Any vaccination or planned vaccination 30 days prior to dosing, or planned vaccination 8 weeks post dosing - Previously received AAV or adenoviral therapy or participation in any previous gene therapy trial
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Part 1 Cohort 1, dose #1 |
Dose #1 of VV-14303 will be administered |
|
|
Experimental Part 1 Cohort 2, dose #2 |
Dose #2 of VV-14303 will be administered |
|
|
Experimental Part 1 Cohort 3, dose #3 |
Dose #3 of VV-14303 will be administered |
|
|
Experimental Part 2 dose |
VV-14303 will be administered at the dose determined from Part 1 (Cohorts 1, 2, and 3) |
|
Recruiting Locations
Kriya Clinical Trial Site
Lady Lake, Florida 32159
Lady Lake, Florida 32159
More Details
- Status
- Recruiting
- Sponsor
- Kriya Therapeutics, Inc.
Detailed Description
A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults with Metabolic dysfunction associated steatohepatitis (MASH) (the RESTORE Study)